Piper Jaffray increased its price target on Osiris after the company reported higher than expected biosurgery sales. The firm thinks that the company's Prochymal product, the first-ever approved stem cell therapy, could allow it to become profitable. It reiterates an Overweight rating on the stock.
- Investment & Company Information
- Piper Jaffray